InMed Pharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent Application 16/644,484 Titled "Metabolic Engineering Of E. Coli For The Biosynthesis Of Cannabinoid Products"
InMed Pharmaceuticals已收到批准其美国专利申请 16/644,484 的通知，该专利名为 “用于大麻素产品生物合成的大肠杆菌代谢工程”